← Back to Clinical Trials
Recruiting NCT07017608

NCT07017608 Inspiratory Work of Breathing Before and After Extubation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07017608
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Lung Transplant; Complications
Study Type OBSERVATIONAL
Enrollment 67 participants
Start Date 2020-09-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 67 participants in total. It began in 2020-09-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Critically ill patients who (1) are not able to maintain their airway, (2) cannot breathe on their own, or (3) both, are ones who often require tracheal intubation and support from a breathing machine (mechanical ventilator). When the patient is ready to be liberated from the mechanical ventilator because the initial insult for intubation has been resolved, the patient is screened using the readiness to wean test in preparation for extubation. As the patient passes this screening, a spontaneous breathing test (SBT) is initiated. Currently, there are many debates surrounding which SBT technique is most favorable. At Toronto General Hospital, the clinical team uses a zero-end expiratory pressure (ZEEP) trial. Once the patient successfully passes their SBT they are then extubated. The patient will undergo a spontaneous breathing trial of continuous positive airway pressure (CPAP) of 5 cmH2O and ZEEP, in which time the investigators will be using a new technology called electrical impedance tomography (EIT), to study and compare the end expiratory lung volume (EELV); investigators will use an esophageal catheter to measure and monitor pressures in the lung, and also assess the patient's work of breathing. This will be repeated once the patient has been extubated safely.

Eligibility Criteria

Inclusion Criteria: * Adult patients intubated and ventilated Exclusion Criteria: * Contraindication for esophageal catheter insertion: upper gastrointestinal surgery within prior 6 weeks, actively bleeding esophageal varices * Bronchopleural fistula * Contraindication for electrical impedance tomography: chest burns, skin lesions in the thorax, chest wall bandaging limiting electrode placement, unstable spinal lesions or fractures * Pregnancy

Contact & Investigator

Central Contact

Glauco Plens, MD

✉ Glauco.Plens@uhn.ca

📞 416-340-4800

Principal Investigator

Ewan Goligher, MD

PRINCIPAL INVESTIGATOR

University Health Network, Toronto

Frequently Asked Questions

Who can join the NCT07017608 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplant; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07017608 currently recruiting?

Yes, NCT07017608 is actively recruiting participants. Contact the research team at Glauco.Plens@uhn.ca for enrollment information.

Where is the NCT07017608 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT07017608 clinical trial?

NCT07017608 is sponsored by University Health Network, Toronto. The principal investigator is Ewan Goligher, MD at University Health Network, Toronto. The trial plans to enroll 67 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology